Outcome of the Board Meeting held on February 07, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Standalone revenue from operations grew 14.3% YoY in Q3 FY26 to ~₹14.26 Cr (vs ~₹12.48 Cr in Q3 FY25); 9M FY26 revenue rose ~10.8% YoY to ~₹41.40 Cr. Q3 PAT was ~₹2.65 Cr vs ~₹2.91 Cr YoY (mild dip), while 9M FY26 PAT stood at ~₹8.06 Cr. EBITDA margin compressed sharply in Q3 (~33% to ~28%) as raw material and employee costs rose faster than revenue. The Board approved a ~₹8 Cr capacity expansion (machines and assembly equipment for cages and needle rollers), expected to deliver 20–25% volume growth over 2 years starting Q1 FY27 — current capacity will be nearly fully utilised by Q4 FY26, funded entirely from internal accruals. The Limited Review Report by Walker Chandiok & Co LLP is clean (unqualified). Company Secretary Ms. Pooja Ponda resigned effective 29 Jan 2026.
Capacity expansion backed by orders beyond current capacity signals strong demand visibility and a clear multi-year growth runway — supportive for the stock. However, the sharp Q3 EBITDA margin compression is a watch-out for near-term profitability, which may temper the positive reaction.